Skip to content

Ambispective Study to Assess the Safety and the Performance of SAGITTA EVL R Stem

Ambispective Study to Assess the Safety and the Performance of SAGITTA EVL R Stem

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06096155
Acronym
2022-09
Enrollment
46
Registered
2023-10-23
Start date
2023-06-13
Completion date
2024-06-06
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Arthropathy

Keywords

Total Hip Prosthesis Revision

Brief summary

This clinical study is conducted to collect data on hip arthroplasty with the SAGITTA EVL-R revision femoral stems manufactured by SERF. This study will confirm the performance and safety of the SAGITTA EVL R revision femoral stems within the framework of MDR 2017/745 and in relation to the recommendations of the MEDDEV guide 2.7.1. Rev 4 (Clinical Evaluation Guide), which provides for a systematic procedure to monitor clinical data in order to verify the claimed performance of medical devices. The primary objective is to evaluate the long-term survival rate (7 to 10 years post-op +/- 2 years) of SAGITTA EVL R stems. Secondary objectives are to : * study long term patient satisfaction with their hip prosthesis, * confirm the long-term safety of these implants by studying the possible complications observed, * evaluate the performance of these implants using clinical scores.

Interventions

None listed

Sponsors

Societe dEtude, de Recherche et de Fabrication
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old at the time of surgery, * Patient implanted with a SAGITTA EVL R revision femoral stem within its indications between 01/01/2010 and 31/12/2015, * Affiliated to French health insurance system

Exclusion criteria

* Patient who has rejected to the use of his/her personal data, * Patient unable to understand the surgeon's instructions or to carry out the post-operative follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Survival Rate at Mid/Long Term Follow-upAt 7/10 years after surgeryAssess the survival rate at 7/10 year-follow-up, whatever the cause of revision

Secondary

MeasureTime frameDescription
Patient's SatisfactionAt 7/10 years after surgeryAssessed by the surgeon through questionary with a 5 item-scale : very satisfied / satisfied / neither satisfied - nor unsatisfied / unsatisfied / very unsatisfied
Adverse EventsAt 7/10 years after surgeryList type and occurence of adverse events
Oblivion of ProsthesisAt 7/10 years after surgeryAssess the degree of forgetfulness of the prosthesis using FJS-score : FJS stands for Forgotten Joint Score. The Forgotten Joint Score assessment consists of 12 questions and is scored on a 0-100 scale. The higher the score, the less the patient is aware of their affected joint when performing daily activities
Absence of SqueakingAt 7/10 years after surgeryNumber of patients experiencing no squeaking
Functional ImprovementAt 7/10 years after surgeryThe only measure to be considered is "Modified Harris Hip Score" which consists of a 0 to 100 points scale (100 points is the better outcome). The data retrieved from site is only 1 figure ranging from 0 to 100.

Countries

France

Baseline characteristics

Characteristic
Age, Continuous79 years
STANDARD_DEVIATION 7.44
Hip side
left
18 number of implants
Hip side
right
28 number of implants
Race/Ethnicity, Customized
French nationality
46 number of implants
Region of Enrollment
France
46 number of implant
Sex: Female, Male
Female
27 number of implants
Sex: Female, Male
Male
19 number of implants
Size166 cm
STANDARD_DEVIATION 9.5
Weight74.9 kg
STANDARD_DEVIATION 19.2

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
23 / 43
other
Total, other adverse events
8 / 46
serious
Total, serious adverse events
15 / 46

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026